| Record Information |
|---|
| Version | 2.0 |
|---|
| Created at | 2024-09-10 19:46:29 UTC |
|---|
| Updated at | 2024-09-10 19:46:29 UTC |
|---|
| NP-MRD ID | NP0334743 |
|---|
| Secondary Accession Numbers | None |
|---|
| Natural Product Identification |
|---|
| Common Name | Testosterone enanthate |
|---|
| Description | Testosterone enanthate, also known as delatestryl or malogen l.A., Belongs to the class of organic compounds known as steroid esters. Steroid esters are compounds containing a steroid moiety which bears a carboxylic acid ester group. Testosterone enanthate can also be converted to estradiol by aromatase, which may lead to gynecomastia in males. It is or has been marketed under a variety of other brand names as well, including, among others:Andro LAAndropositoryDepandroDurathateEveroneTestostrovalTestrinTestro LAXyostedTestosterone enanthate is available in the United States and widely elsewhere throughout the world. Testosterone enanthate is a drug. Testosterone enanthate is a very hydrophobic molecule, practically insoluble (in water), and relatively neutral. Testosterone enanthate was first documented in 1985 (PMID: 4028529). Side effects of testosterone enanthate include symptoms of masculinization like acne, increased hair growth, voice changes, and increased sexual desire (PMID: 16185098) (PMID: 15329035) (PMID: 17530941) (PMID: 17484401) (PMID: 12792150). |
|---|
| Structure | [H][C@@]12CC[C@H](OC(=O)CCCCCC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C InChI=1S/C26H40O3/c1-4-5-6-7-8-24(28)29-23-12-11-21-20-10-9-18-17-19(27)13-15-25(18,2)22(20)14-16-26(21,23)3/h17,20-23H,4-16H2,1-3H3/t20-,21-,22-,23-,25-,26-/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| 17-((1-Oxoheptyl)oxy)androst-4-en-3-one | ChEBI | | 17-Hydroxyandrost-4-en-3-one, 17-heptanoate | ChEBI | | 17beta-Hydroxyandrost-4-en-3-one heptanoate | ChEBI | | Testosterone 17-enanthate | ChEBI | | Testosterone heptanoate | ChEBI | | Delatestryl | Kegg | | 17-Hydroxyandrost-4-en-3-one, 17-heptanoic acid | Generator | | 17b-Hydroxyandrost-4-en-3-one heptanoate | Generator | | 17b-Hydroxyandrost-4-en-3-one heptanoic acid | Generator | | 17beta-Hydroxyandrost-4-en-3-one heptanoic acid | Generator | | 17Β-hydroxyandrost-4-en-3-one heptanoate | Generator | | 17Β-hydroxyandrost-4-en-3-one heptanoic acid | Generator | | Testosterone 17-enanthic acid | Generator | | Testosterone heptanoic acid | Generator | | Testosterone enanthic acid | Generator | | 17beta-Enanthoxyandrost-4-en-3-one | HMDB | | 17beta-Hydroxyandrost-4-en-3-one enanthate | HMDB | | 4-Androsten-17beta-ol-3-one 17-enanthate | HMDB | | 4-Androsten-3-one 17beta-enanthate | HMDB | | Androgyn l.a. | HMDB | | Andropository | HMDB | | Androtardyl | HMDB | | Atlatest | HMDB | | DEA no. 4000 | HMDB | | Delatest | HMDB | | DePatestrye | HMDB | | Depo-testro med | HMDB | | Ditate | HMDB | | Durathate | HMDB | | Everone | HMDB | | Exten test | HMDB | | Malogen l.a. | HMDB | | Malogen l.a.200 | HMDB | | Orquisteron-e | HMDB | | Primotestone | HMDB | | Reposo TMD | HMDB | | Testanthate | HMDB | | Testate | HMDB | | Testenate | HMDB | | Testinon | HMDB | | Testoenant | HMDB | | Testonenant | HMDB | | Testosterone 17beta-heptanoate | HMDB | | Testosterone 17beta-heptanoic acid | HMDB | | Testosterone enantate | HMDB | | Testosterone heptoate | HMDB | | Testosterone heptoic acid | HMDB | | Testosterone heptylate | HMDB | | Testosterone oenanthate | HMDB | | Testostroval | HMDB | | BTG Brand OF testosterone enanthate | HMDB | | Jenapharm brand OF testosterone enanthate | HMDB | | Rotexmedica brand OF testosterone enanthate | HMDB | | Testosteron-depot jenapharm | HMDB | | Pasadena brand OF testosterone enanthate | HMDB | | Primoteston depot | HMDB | | Rugby brand OF testosterone enanthate | HMDB | | Testosteron depot-rotexmedica | HMDB | | Testosteron-depot eifelfango | HMDB | | Testrin p.a. | HMDB | | Roberts brand OF testosterone enanthate | HMDB | | Eifelfango brand OF testosterone enanthate | HMDB | | Schering brand OF testosterone enanthate | HMDB | | Theramed brand OF testosterone enanthate | HMDB | | Theramex | HMDB |
|
|---|
| Chemical Formula | C26H40O3 |
|---|
| Average Mass | 400.5940 Da |
|---|
| Monoisotopic Mass | 400.29775 Da |
|---|
| IUPAC Name | (1S,2R,10R,11S,14S,15S)-2,15-dimethyl-5-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-14-yl heptanoate |
|---|
| Traditional Name | everone |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | [H][C@@]12CC[C@H](OC(=O)CCCCCC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C |
|---|
| InChI Identifier | InChI=1S/C26H40O3/c1-4-5-6-7-8-24(28)29-23-12-11-21-20-10-9-18-17-19(27)13-15-25(18,2)22(20)14-16-26(21,23)3/h17,20-23H,4-16H2,1-3H3/t20-,21-,22-,23-,25-,26-/m0/s1 |
|---|
| InChI Key | VOCBWIIFXDYGNZ-IXKNJLPQSA-N |
|---|
| Experimental Spectra |
|---|
|
| Not Available | | Predicted Spectra |
|---|
|
| Not Available | | Chemical Shift Submissions |
|---|
|
| Not Available | | Species |
|---|
| Species of Origin | Not Available |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as steroid esters. Steroid esters are compounds containing a steroid moiety which bears a carboxylic acid ester group. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Lipids and lipid-like molecules |
|---|
| Class | Steroids and steroid derivatives |
|---|
| Sub Class | Steroid esters |
|---|
| Direct Parent | Steroid esters |
|---|
| Alternative Parents | |
|---|
| Substituents | - Steroid ester
- Androgen-skeleton
- Androstane-skeleton
- 3-oxosteroid
- 3-oxo-delta-4-steroid
- Oxosteroid
- Delta-4-steroid
- Cyclohexenone
- Ketone
- Carboxylic acid ester
- Cyclic ketone
- Monocarboxylic acid or derivatives
- Carboxylic acid derivative
- Organooxygen compound
- Carbonyl group
- Organic oxide
- Organic oxygen compound
- Hydrocarbon derivative
- Aliphatic homopolycyclic compound
|
|---|
| Molecular Framework | Aliphatic homopolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Predicted Properties | |
|---|
| General References | - Darby E, Anawalt BD: Male hypogonadism : an update on diagnosis and treatment. Treat Endocrinol. 2005;4(5):293-309. doi: 10.2165/00024677-200504050-00003. [PubMed:16185098 ]
- Gooren LJ, Bunck MC: Androgen replacement therapy: present and future. Drugs. 2004;64(17):1861-91. doi: 10.2165/00003495-200464170-00002. [PubMed:15329035 ]
- Rogerson S, Weatherby RP, Deakin GB, Meir RA, Coutts RA, Zhou S, Marshall-Gradisnik SM: The effect of short-term use of testosterone enanthate on muscular strength and power in healthy young men. J Strength Cond Res. 2007 May;21(2):354-61. doi: 10.1519/R-18385.1. [PubMed:17530941 ]
- Giuberti A, Manganini V, Picozzi SC, Vigano P, Strada GR: Complete genital prosthetization in patients treated with bilateral orchiectomy for metachronous testicular cancer. Arch Ital Urol Androl. 2007 Mar;79(1):26-9. [PubMed:17484401 ]
- Schustack A, Meshiaj D, Waiss Z, Gotloib L: Intramuscular iron replenishment and replacement combined with testosterone enanthate in maintenance hemodialysis anemia: a follow-up of up to 8 years on 16 patients. Clin Nephrol. 1985 Jun;23(6):303-6. [PubMed:4028529 ]
- Schubert M, Bullmann C, Minnemann T, Reiners C, Krone W, Jockenhovel F: Osteoporosis in male hypogonadism: responses to androgen substitution differ among men with primary and secondary hypogonadism. Horm Res. 2003;60(1):21-8. doi: 10.1159/000070823. [PubMed:12792150 ]
|
|---|